Tuesday July 17, 2018
Home India Vivo Y53i Lau...

Vivo Y53i Launched As Budget Smartphone in India

New Vivo budget smartphone with 'Ultra-HD' technology in India

0
//
30
Representational image.
Representational image. Pixabay
Republish
Reprint

Expanding its “Y” series, Chinese handset maker Vivo on Monday launched “Y53i” smartphone with Ultra-HD technology and “face access” feature in India for Rs 7,990.

The 8MP rear camera houses “Ultra HD” technology that helps shoot several consecutive images and combines them to render clear and detailed photos with a resolution of up to 32MP.

The budget device also has “Screen Flash” feature that claims to provide detailed selfies even in low-light conditions.

The smartphone will be available in crown gold and matte black colours across all offline stores, the company said in a statement.

“With the introduction of Y53i, we are strengthening our budget smartphone portfolio by delivering an outstanding camera and user experience at a competitive price point,” said Kenny Zeng, CMO, Vivo India.

Also Read: Vivo opens online store in India

The device has 5-inch display, 5MP selfie camera, 2GB RAM and 16GB ROM which is expandable up to 256GB.

Powered by Qualcomm Snapdragon 425 processor, “Vivo Y53i” also features a 2500mAh battery.

The handset houses “smart eye protection” that filters out blue light to prevent eye strain and “App clone” function to make multitasking easier.  IANS

Click here for reuse options!
Copyright 2018 NewsGram

Next Story

Cepheid to Establish Manufacturing Unit for TB Diagnostics in India

Rifampicin is a drug commonly used in treating TB bacteria in first line of treatment

0
The GeneXpert Edge is developed specifically for near-patient testing, to help support a one visit test-and-treat approach.
The GeneXpert Edge is developed specifically for near-patient testing, to help support a one visit test-and-treat approach. (IANS)

Expanding its footprint in India, US-based molecular diagnostics company Cepheid Inc on Thursday announced its plans to establish a manufacturing unit in the country to improve Tuberculosis (TB) diagnostics.

Cepheid’s GeneXpert MTB/RIF test is a closed-cartridge-based system that is easy to operate by minimally trained staff and gives results in approximately two hours, speeding the conventional backlog that used to exist in traditional diagnostic methods.

The new manufacturing unit would produce MTB/RIF test cartridges, contribute to the government’s “Make in India” initiative and thus bringing the company’s global expertise in TB diagnostics to India, the company said in a statement.

As part of the plan, Cepheid also unveiled its latest portable, easy-to-use TB-testing system — the GeneXpert Edge — which is expected to be available in India later this year, the company said.

The GeneXpert Edge is developed specifically for near-patient testing, to help support a one visit test-and-treat approach.

“Cepheid recognises the need for technological advancement and is committed to contributing significantly to India’s goal of TB eradication,” said Peter Farrell, Executive Vice President, Worldwide Commercial Operations, Cepheid.

Cepheid's Xpert MTB/RIF test has the potential to detect Mycobacterium tuberculosis(MTB)
Cepheid’s Xpert MTB/RIF test has the potential to detect Mycobacterium tuberculosis(MTB).

“We are hopeful that GeneXpert Edge will help eliminate delays in TB diagnostics by providing definitive results within hours and facilitating fast and easy last-mile delivery even in the remote villages of India,” he added.

India has nearly one-fourth of the global TB patients and an estimated 4.8 lakh lives are lost every year due to delayed diagnosis and inadequate treatment and there are above 2.5 million new cases of TB every year. The country aims to eradicate TB by 2025.

Approved by the World Health Organisation (WHO) in 2010, more than 1,200 Cepheid’s GeneXpert Systems have been installed in the last two years at various Revised National Tuberculosis Control Programme (RNTCP) sites in the country and more than 2.5 million cartridges were supplied last year at various centres of Central TB Division (CTD).

Also Read: Fruit Bats Identified As Source Of Nipah Virus Outbreak in Kerala

Cepheid’s Xpert MTB/RIF test has the potential to detect Mycobacterium tuberculosis(MTB) and rifampicin-resistance mutations, which are markers for MDR-TB strains in under two hours.

Rifampicin is a drug commonly used in treating TB bacteria in first line of treatment.

Xpert MTB/RIF tests also have excellent negative predictive value, which allows clinicians to manage TB-negative patients more effectively to prevent unnecessary and costly respiratory isolations. (IANS)

Next Story